💊 Sildenafil Citrate — Complete Drug File

1. DRUG IDENTITY

2. AVAILABLE FORMULATIONS

3. MECHANISM OF ACTION

Critically: sildenafil does not create an erection on its own. Sexual arousal and NO release must precede its action.

4. PHARMACOKINETICS (ADME)

5. THERAPEUTIC INDICATIONS

A. Erectile Dysfunction (ED)

• First-line therapy for ED across all etiologies: organic, psychogenic, and mixed
• Effective regardless of baseline severity, age, or race
• Efficacy rates: 56–84% of men on 25–100 mg vs. 25% placebo
• Specific efficacy: 70% in hypertensives, 57% in diabetics, 43% post-radical prostatectomy, 80% in spinal cord injury
• Also effective in men with coronary artery disease, depression, post-TURP, spina bifida, and those on antidepressants/antipsychotics/antihypertensives
• Off-label (women): Some evidence for SSRI-induced anorgasmia and sexual inhibition

B. Pulmonary Arterial Hypertension (PAH) — FDA approved

• Improves exercise capacity, functional class (WHO), and hemodynamics
• Sildenafil 20 mg TID (adult) is the approved PAH dose
• Combined with long-term epoprostenol therapy → delays clinical worsening of PAH
• Controlled trial data supports its use in idiopathic PAH

C. Other / Investigational Uses

• COPD with mild pulmonary hypertension — studied for acute hemodynamic effects
• Pulmonary fibrosis / interstitial lung disease — antifibrotic properties under investigation
• Facilitating weaning from inhaled nitric oxide (neonates and infants — limited data)
• Portal hypertension — anecdotal/case reports

6. DOSAGE AND ADMINISTRATION

Erectile Dysfunction (Adult)

Pulmonary Arterial Hypertension (Adult)

• Oral: 20 mg TID (at least 4–6 hours apart)
• IV: 10 mg TID
• Can be titrated to 40–80 mg TID in combination with epoprostenol

Pediatric (PAH) — Limited data; use with caution

7. ADVERSE EFFECTS

Common (dose-dependent)

Visual Effects

• Transient blue-green tinting of vision (cyanopsia) — due to inhibition of retinal PDE6 (involved in phototransduction); mild and transient
• Increased light sensitivity, blurred vision
• Non-arteritic anterior ischemic optic neuropathy (NAION) — rare but serious; sudden vision loss; shared risk factors with ED (age, DM, HTN, dyslipidemia); causal link not established. Advise patients to stop sildenafil and seek urgent care if sudden vision loss occurs.
• Risk of severe retinopathy of prematurity in neonates (due to color discrimination impairment)

Serious / Rare

• Priapism (prolonged painful erection — urologic emergency)
• Sudden hearing loss / sensorimpairment — temporal association reported; FDA mandated label update 2007
• Severe hypotension — when combined with nitrates (can be fatal)
• Myocardial infarction — not directly caused by sildenafil per FDA analysis, but sexual activity increases cardiac O₂ demand

8. CONTRAINDICATIONS

9. DRUG INTERACTIONS

Pharmacokinetic (CYP3A4/2C9-based)

Pharmacodynamic

No significant laboratory interferences reported.

10. SPECIAL POPULATIONS

11. CARDIOVASCULAR SAFETY CONSIDERATIONS

• FDA concluded that sildenafil does not independently increase MI or death risk when used per approved labeling
• Sexual intercourse itself increases cardiac O₂ demand — cardiovascular evaluation (including exercise tolerance assessment and nitrate use review) is recommended before prescribing in men with:
  • Prior MI, stroke, or renal failure
  • Hypertension or diabetes
  • Age >70 years
• No pharmacologic antidote exists for the PDE5 inhibitor–nitrate interaction

12. COMPARISON WITH OTHER PDE5 INHIBITORS

13. STORAGE AND STABILITY

• Store at room temperature, protected from moisture and light
• Oral suspension (Revatio): discard unused portion per label instructions; contains sodium benzoate

• Goodman & Gilman's The Pharmacological Basis of Therapeutics, 14th Ed. — PDE5 Inhibitors section
• The Harriet Lane Handbook, 23rd Ed. (Johns Hopkins) — Formulary, pp. 1345–1346
• Smith and Tanagho's General Urology, 19th Ed. — pp. 631–632
• Kaplan & Sadock's Synopsis of Psychiatry — pp. 2129–2133
• Murray & Nadel's Textbook of Respiratory Medicine
• Goldman-Cecil Medicine, International Ed.

Prevalence of Erectile Dysfunction (ED) in Africa

Overview

1. General Population Estimates

The wide CIs in meta-analyses reflect significant heterogeneity in study designs, populations, and ED assessment tools across African settings.

2. ED in Diabetic Men — Particularly High Burden

• Ethiopia (meta-analysis, 2021): Pooled prevalence of ED in diabetic men = 54.3%. Older age (OR 4.42) and longer DM duration (OR 3.2) were the strongest independent predictors. [PMID: 33583238]
• Nigeria (2025 study): Among Nigerian type-2 diabetic men, independent predictors of ED included:
  • Age >60 years (OR 4.9)
  • Serum testosterone <270 ng/mL (OR 3.8)
  • LDL >160 mg/dL (OR 6.3) — strongest predictor
  • Hypertension (OR 2.93)
  • FBS >125 mg/dL (OR 2.6)
  • Triglycerides >150 mg/dL (OR 2.9) [PMID: 40618378]
• Global meta-analysis (2017, 145 studies): ED prevalence in all diabetic men worldwide was ~52%; Africa-specific subgroup data not separately reported but consistent with global trend [PMID: 28722225]

3. Risk Factors Identified Across African Studies

4. Healthcare-Seeking Behavior and Underreporting

• In the Nigerian (Bida) study, 66.4% of men with ED had used performance-enhancing drugs — predominantly traditional and OTC remedies — yet only 5.6% had ever formally reported ED to a healthcare provider [PMID: 38787782]
• A 2025 systematic review on African medicinal plants for ED [PMID: 42008323] confirms that traditional medicine use is widespread across the continent, driven by stigma, cost barriers, and cultural norms
• The South African systematic review found only 5 published articles on male sexual dysfunction in South Africa since 1970 — illustrating the research gap [PMID: 26301289]

5. Research Gaps and Limitations

• No continent-wide prevalence study exists for Africa; available data are fragmented by country, setting (hospital vs. community), and methodology
• Most African studies are hospital/clinic-based, likely overrepresenting men with comorbidities → true community prevalence may differ
• The IIEF-5 is the dominant tool used but not validated for all African language/cultural contexts
• North Africa (Egypt, Tunisia) and West/East Africa (Nigeria, Ethiopia) are better represented; Central Africa and francophone Sub-Saharan Africa have minimal data
• Underreporting due to stigma means all published figures likely underestimate the true burden

6. Comparison with Global Estimates

Summary

• Prevalence of ED in North-West Nigeria, 2023 — PMID 38223611
• Prevalence of ED in Bida, Nigeria, 2024 — PMID 38787782
• ED in Ethiopian diabetics — meta-analysis, 2021 — PMID 33583238
• ED predictors in Nigerian T2DM men, 2025 — PMID 40618378
• ED risk factors in Upper Egypt, 2010 — PMID 20795441
• Sexual dysfunction in South Africa — systematic review, 2014 — PMID 26301289
• Traditional approaches to ED in Africa, 2025 — PMID 42008323

Age-Based ED Prevalence — African Studies

Nigeria (Bida, Federal Medical Centre) — PMID 38787782

Age-stratified data for intermediate decades (30s, 40s, 50s, 60s) were not broken out in the abstract — only the youngest and oldest extremes were reported.

Nigeria (Kano, Primary Care Clinic) — PMID 38223611

This study did not publish a full age-stratified table in the abstract — it reported age ≥50 as a significant cut-off predictor rather than decade-by-decade rates.

Nigeria (Type 2 Diabetic Men) — PMID 40618378

Again, no decade-by-decade prevalence table — age >60 yr reported as the key threshold.

Ethiopia (Diabetic Men, Meta-Analysis) — PMID 33583238

No age-decade breakdown — older age was treated as a continuous/categorical predictor.

Egypt (Upper Egypt, Risk Factor Study) — PMID 20795441

Key Takeaway

Mechanism of Action — Sildenafil Citrate

The Normal Erectile Cascade (Physiological Basis)

Sexual Stimulation
       ↓
Penile nerve endings + vascular endothelium
release Nitric Oxide (NO)
       ↓
NO diffuses into cavernous & vascular smooth muscle cells
       ↓
NO activates Guanylyl Cyclase (GC)
       ↓
GTP → cGMP (cyclic guanosine monophosphate) ↑
       ↓
cGMP activates Protein Kinase G (PKG)
       ↓
PKG → ↓ intracellular Ca²⁺
       ↓
Smooth muscle RELAXATION
       ↓
Vasodilation of penile arterioles + relaxation of
corpus cavernosum smooth muscle
       ↓
↑ Blood inflow → Penile ERECTION
       ↓
PDE5 degrades cGMP → erection terminates

Where Sildenafil Acts

• Prevents cGMP degradation
• Elevates and prolongs intracellular cGMP levels
• Sustains PKG signalling → sustained smooth muscle relaxation → prolonged erection

Molecular Target Detail

Critical Clinical Implication of the Mechanism

Sildenafil does NOT cause erection in the absence of sexual stimulation.

• NO is not released
• Guanylyl cyclase is not activated
• No cGMP is produced → sildenafil has nothing to preserve → no erection occurs

Mechanism in Pulmonary Arterial Hypertension (PAH)

Endogenous NO in pulmonary arterial smooth muscle cells (PASMCs)
       ↓
Activates guanylyl cyclase → ↑ cGMP
       ↓
cGMP → pulmonary vascular smooth muscle relaxation
       ↓
↓ Pulmonary vascular resistance (PVR)
       ↓
↓ Right ventricular afterload → improved RV function

Off-Target PDE Inhibition — The Basis of Side Effects

Mechanism Behind the Nitrate Contraindication

Organic nitrates → release exogenous NO
                          ↓
               ↑↑ cGMP production (guanylyl cyclase)
                          +
Sildenafil → blocks cGMP breakdown (PDE5)
                          ↓
         MASSIVE ↑↑↑ cGMP → profound systemic vasodilation
                          ↓
           Severe, potentially fatal HYPOTENSION

Summary Diagram

Sexual stimulation / endogenous NO
            ↓
   Guanylyl Cyclase (active)
            ↓
      GTP ──→ cGMP
                 ↑
        [Sildenafil blocks here]
                 ↓
    PDE5 ──→ GMP (inactive)
       [INHIBITED by sildenafil]

  Net effect: ↑↑ cGMP → ↑ PKG → ↓ Ca²⁺
           → Smooth muscle relaxation
           → Vasodilation / Erection / ↓ PVR

• Goodman & Gilman's Pharmacological Basis of Therapeutics, 14th Ed. — PDE5 Inhibitors, p. 719
• Smith and Tanagho's General Urology, 19th Ed. — pp. 631–632
• Kaplan & Sadock's Synopsis of Psychiatry — pp. 2129–2130